NEW YORK, September 30, 2016 /PRNewswire/ --
An important step in discovering new treatments for cancer and any sort of disease, as well as new ways to identify, analyze, and decrease the risk of disease, is by performing clinical trials. This shows researchers the many approaches we are capable of and while revealing the possible side effects of treatments. Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM), Kite Pharma Inc. (NASDAQ: KITE), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), Puma Biotechnology Inc. (NYSE: PBYI), Juno Therapeutics Inc. (NASDAQ: JUNO).
Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM) made headlines after the recent announcement of commencing Phase II clinical trials of the company's most advanced alpha particle immunotherapy, Actimab-A, in patients above the age of 60 who were newly diagnosed with Acute Myeloid Leukemia (AML). The Actimab-A alpha particle immunotherapy program consists of the CD33 (a protein on AML cells) targeting monoclonal antibody (HuM195) and the actinium-225, a promising therapeutic radionuclide to target alpha therapy of cancer and infectious diseases.
Actinium's Phase II clinical trial consists of 53 patients who will be given Actimab-A in a low dose (2.0 µCi/kilogram/fractionated) of its Actimab-A through two injections given on the first and seventh day of treatment. The objective of Phase II is to determine if Lintuzumab-225 and cytarabine, a standard chemotherapy drug, can regulate AML and also the safety of this drug combination. Lintuzumab is a monoclonal antibody that targets CD33 and Ac-225 is a radioactive substance. The Phase II trial is designed to gauge complete response rates at up to day 42 after Actimab-A administration while determining the antileukemic effects, including its ability to produce complete remissions, of Lintuzumab-Ac225.
Actinium Pharmaceuticals Inc. (ATNM) has decided to incorporate peripheral blast burden as an inclusion criteria and in patients with high peripheral blast burden, the use of Hydroxyurea will be directed with the aim of bringing peripheral blast burden below a key threshold number that the Company has performed from two previously finished Phase 1 clinical trials consisting of 38 patients. Furthermore, will mandate the use of granulocyte colony-stimulating factors. Low dose cytarabine has been removed from the procedure and the Phase 2 clinical trial will assess Actimab-A as a monotherapy. Overall survival will be its secondary endpoint of Phase II clinical trials.
Actinium Pharmaceuticals Inc. (ATNM) Executive Chairman, Sandesh Seth stated, "We are excited to have initiated the Phase 2 trial of Actimab-A for elderly patients who are newly diagnosed with AML and ineligible for 7+3 treatment. These older patients face a poor prognosis and have limited viable treatment options. We are encouraged by the safety and efficacy signals we have seen thus far and look forward to the execution of this trial with an eye toward interim and top-line results which are both expected in 2017."
Clinical-stage biopharmaceutical company, Kite Pharma Inc. (NASDAQ: KITE) recently announced their latest results from a pre-planned interim analysis ZUMA-1 (Phase II clinical trial) of the company's most advanced candidate, KTE-C19, had met its primary endpoint objective. KTE-C19 revealed that 76 percent of patients that has Non-Hodgkin Lymphoma, a cancer that starts in cells called lymphocytes that are part of the body's immune system, responded firmly to the treatment, including 47 percent complete remissions.
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) has publicized its partnership with Otsuka Pharmaceutical, along with regulatory approval for its prescription medication, Iclusig®(ponatinib) from Japanese Pharmaceuticals and Medical Devices Agency. Iclusig is used for the treatment of chronic myeloid leukemia resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia.
U.S. Food and Drug Administration has approved Puma Biotechnology Inc. (NYSE: PBYI) new drug application, PB272 (Neratinib), for extended adjuvant treatment of HER2-positive early stage breast cancer. Neratinib allows the company to treat patients with overexpressed breast cancer who have also had prior adjuvant breast cancer therapy with Herceptin (trastuzumab). Puma Biotechnology is a biopharmaceutical company devoted to the acquisition and development of novel therapeutics for the treatment of cancer.
Researchers from the Fred Hutchinson Cancer Research center shared data results from patients with advanced non-Hodgkin Lymphoma who received Chimeric Antigen Receptor T-Cell treatment and chemotherapy, JCAR014. This was a key study for Juno Therapeutics Inc. (NASDAQ: JUNO) in order to further develop its similar product candidate for the treatment of CD19 positive blood cancers, JCAR017. Patients received intermediate doses of JCAR014 had an overall response rate of 82 percent (9/11), thus showing promising early effectiveness of the treatment. Complete response rate was 64 percent (7/11), Severe Cytokine Release Syndrome was 9 percent, and Severe Neurotoxicity was 18 percent (2/11).
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated twelve thousand dollars for financial news pr services by a non-affiliated third party for biosig technologies inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact: Danny A., [email protected] , +1-877-601-1879
SOURCE FinancialBuzz.com
Advertisement
An important step in discovering new treatments for cancer and any sort of disease, as well as new ways to identify, analyze, and decrease the risk of disease, is by performing clinical trials. This shows researchers the many approaches we are capable of and while revealing the possible side effects of treatments. Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM), Kite Pharma Inc. (NASDAQ: KITE), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), Puma Biotechnology Inc. (NYSE: PBYI), Juno Therapeutics Inc. (NASDAQ: JUNO).
Advertisement
Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM) made headlines after the recent announcement of commencing Phase II clinical trials of the company's most advanced alpha particle immunotherapy, Actimab-A, in patients above the age of 60 who were newly diagnosed with Acute Myeloid Leukemia (AML). The Actimab-A alpha particle immunotherapy program consists of the CD33 (a protein on AML cells) targeting monoclonal antibody (HuM195) and the actinium-225, a promising therapeutic radionuclide to target alpha therapy of cancer and infectious diseases.
Actinium's Phase II clinical trial consists of 53 patients who will be given Actimab-A in a low dose (2.0 µCi/kilogram/fractionated) of its Actimab-A through two injections given on the first and seventh day of treatment. The objective of Phase II is to determine if Lintuzumab-225 and cytarabine, a standard chemotherapy drug, can regulate AML and also the safety of this drug combination. Lintuzumab is a monoclonal antibody that targets CD33 and Ac-225 is a radioactive substance. The Phase II trial is designed to gauge complete response rates at up to day 42 after Actimab-A administration while determining the antileukemic effects, including its ability to produce complete remissions, of Lintuzumab-Ac225.
Actinium Pharmaceuticals Inc. (ATNM) has decided to incorporate peripheral blast burden as an inclusion criteria and in patients with high peripheral blast burden, the use of Hydroxyurea will be directed with the aim of bringing peripheral blast burden below a key threshold number that the Company has performed from two previously finished Phase 1 clinical trials consisting of 38 patients. Furthermore, will mandate the use of granulocyte colony-stimulating factors. Low dose cytarabine has been removed from the procedure and the Phase 2 clinical trial will assess Actimab-A as a monotherapy. Overall survival will be its secondary endpoint of Phase II clinical trials.
Actinium Pharmaceuticals Inc. (ATNM) Executive Chairman, Sandesh Seth stated, "We are excited to have initiated the Phase 2 trial of Actimab-A for elderly patients who are newly diagnosed with AML and ineligible for 7+3 treatment. These older patients face a poor prognosis and have limited viable treatment options. We are encouraged by the safety and efficacy signals we have seen thus far and look forward to the execution of this trial with an eye toward interim and top-line results which are both expected in 2017."
Clinical-stage biopharmaceutical company, Kite Pharma Inc. (NASDAQ: KITE) recently announced their latest results from a pre-planned interim analysis ZUMA-1 (Phase II clinical trial) of the company's most advanced candidate, KTE-C19, had met its primary endpoint objective. KTE-C19 revealed that 76 percent of patients that has Non-Hodgkin Lymphoma, a cancer that starts in cells called lymphocytes that are part of the body's immune system, responded firmly to the treatment, including 47 percent complete remissions.
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) has publicized its partnership with Otsuka Pharmaceutical, along with regulatory approval for its prescription medication, Iclusig®(ponatinib) from Japanese Pharmaceuticals and Medical Devices Agency. Iclusig is used for the treatment of chronic myeloid leukemia resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia.
U.S. Food and Drug Administration has approved Puma Biotechnology Inc. (NYSE: PBYI) new drug application, PB272 (Neratinib), for extended adjuvant treatment of HER2-positive early stage breast cancer. Neratinib allows the company to treat patients with overexpressed breast cancer who have also had prior adjuvant breast cancer therapy with Herceptin (trastuzumab). Puma Biotechnology is a biopharmaceutical company devoted to the acquisition and development of novel therapeutics for the treatment of cancer.
Researchers from the Fred Hutchinson Cancer Research center shared data results from patients with advanced non-Hodgkin Lymphoma who received Chimeric Antigen Receptor T-Cell treatment and chemotherapy, JCAR014. This was a key study for Juno Therapeutics Inc. (NASDAQ: JUNO) in order to further develop its similar product candidate for the treatment of CD19 positive blood cancers, JCAR017. Patients received intermediate doses of JCAR014 had an overall response rate of 82 percent (9/11), thus showing promising early effectiveness of the treatment. Complete response rate was 64 percent (7/11), Severe Cytokine Release Syndrome was 9 percent, and Severe Neurotoxicity was 18 percent (2/11).
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated twelve thousand dollars for financial news pr services by a non-affiliated third party for biosig technologies inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact: Danny A., [email protected] , +1-877-601-1879
SOURCE FinancialBuzz.com
